Eulry F, Bauduceau B, Lechevalier D, Magnin J, Crozes P, Flageat J, Gautier D
Service de Rhumatologie, Hôpital d'Instruction des Armées Begin, Saint-Mandé.
Rev Rhum Mal Osteoartic. 1992 Apr;59(4):247-52.
The effect of L-Thyroxine suppressive therapy (207.3 +/- 46.1 mcg/d) on lumbar spine bone density (BMD) was assessed in 51 patients thyroidectomized for carcinoma since 1 to 19 years (mean = 6 +/- 5.4 years); the bone densities of these patients were compared with those of 51 age sex weight-matched control subjects. Trabecular bone density was evaluated by single energy quantitative tomography. The vertebral BMD was not significantly different between the patients receiving suppressive doses of L-T4 and the control group (162.8 +/- 40.4 vs 162.7 +/- 39.8 mg/cm3). We found no relationship between the duration of L-Thyroxine therapy and BMD. Thus, doses of L-T4 sufficient for suppressing plasma thyroid stimulating hormone but no high enough for causing biochemical thyrotoxicosis have no harmful effect on trabecular bone mineral density.
对51例因甲状腺癌接受甲状腺切除术1至19年（平均6±5.4年）的患者，评估了左旋甲状腺素抑制疗法（207.3±46.1微克/天）对腰椎骨密度（BMD）的影响；将这些患者的骨密度与51名年龄、性别、体重匹配的对照受试者进行比较。通过单能定量断层扫描评估小梁骨密度。接受抑制剂量L-T4的患者与对照组之间的椎体骨密度无显著差异（162.8±40.4 vs 162.7±39.8毫克/立方厘米）。我们发现左旋甲状腺素治疗持续时间与骨密度之间无相关性。因此，足以抑制血浆促甲状腺激素但不足以引起生化性甲状腺毒症的L-T4剂量对小梁骨矿物质密度无有害影响。
